Page 3 - Pharma Sector

Eli Lilly to pump $1 billion into India to boost contract manufacturing

The US pharma major to set up a manufacturing and supply hub in Hyderabad as part of a $1 billion investment aimed at boosting contract production in India

Rubicon Research IPO opens Oct 9; key risks, strengths you must know

Rubicon Research IPO is available at a price band of ₹461-485 per share, with a lot size of 30 shares

Health Secy reviews GMP norms with states after cough syrup deaths

Union Health Secretary Punya Salila Srivastava chaired a meeting with states after 11 children died in MP and Rajasthan, stressing strict GMP compliance and rational use of cough syrups in children

IPA appoints Zydus Lifesciences MD Sharvil Patel as new President

Sharvil Patel takes over as President of IPA from Samir Mehta, with Glenn Saldanha appointed Vice President, as the industry navigates reforms and global challenges

Rubicon Research sets IPO price band at ₹461-475; check key dates, lot size

Rubicon Research IPO will open for subscription on Thursday, October 9, 2025, and close on Monday, October 13, 2025

Trump to launch 'TrumpRx', to make drugs cheaper for Americans, says report

After talks with US President Donald Trump, global pharma giant Pfizer is further expected to announce a $70 billion investment in research, development and domestic manufacturing

Datanomics: India doubles its share in prescription drugs to the US

The Indian pharma stocks tanked after the announcement due to the ambiguity surrounding the impact of tariff on complex generics and specialty medicines supplied by the Indian pharma companies

Lupin to acquire VISUfarma BV for €190 mn to expand European eyecare reach

Lupin's unit Nanomi BV will acquire VISUfarma BV from GHO Capital for €190 mn, adding an eyecare portfolio across Europe and strengthening its ophthalmology franchise

Lupin subsidiary Nanomi BV inks pact to acquire Netherlands-based VISUfarma

Drug maker Lupin on Monday said its subsidiary has inked a pact to fully acquire Amsterdam-headquartered VISUfarma BV at an enterprise value of 190 million euros. The company's wholly-owned subsidiary, Nanomi BV has signed a definitive agreement for the acquisition of VISUfarma BV, a portfolio company of global healthcare specialist investor GHO Capital Partners LLP, the Mumbai-based drug maker said in a statement. The acquisition of VISUfarma, with its broad portfolio of eye health products and established commercial infrastructure, aligns with the company's strategy to expand its European business and footprint and to advance the company's global specialty franchise, it added. By integrating VISUfarma's established commercial operations, Lupin will tap into the attractive ophthalmology market, which is experiencing significant global growth driven by an aging global population, the increasing incidence of diabetes-related eye complications, and growing awareness of preventive care

India's pharma exports unlikely to be affected amid Tylenol debate: Experts

Data shows India's paracetamol exports to the US are modest, accounting for less than one per cent of API shipments, despite global attention on the Tylenol controversy

Indian pharma firms likely to dodge immediate impact of Trump's tariff

Trump's 100% tariffs on branded drugs will spare Indian generics, though analysts see exposure for Sun Pharma, Biocon and Aurobindo, with Jubilant Pharmova set to benefit

Nifty Pharma declines 2% after Donald Trump's 100% tariff on branded drugs

The index tracking domestic pharmaceutical stocks hit a low of 21,390 and then recouped some losses to end at 21,507

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Trump announces 100% tariff on pharma imports; duties on trucks, furniture

Trump said the new tariffs would not apply to companies that are actively building pharmaceutical manufacturing facilities in the US

Why Nomura continues to back Glenmark Pharma; Retains 'Buy'; Find out here

Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.

Sun Pharmaceutical: Domestic, innovation push eyed; Nuvama maintains 'Hold'

Sun Pharma aims to strengthen its domestic formulations business through field force expansion and a generic GLP-1 launch in CY26.

Lupin gets tentative nod from USFDA for generic HIV treatment drug

Pharma major Lupin Ltd on Wednesday said it has received tentative approval from the US health regulator for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets used to treat human immunodeficiency virus (HIV) infection. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets of strength 50 mg/200 mg/25 mg, Lupin said in a regulatory filing. This product would be manufactured at Lupin's Nagpur facility, it added. Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets, 50 mg/200 mg/25 mg are bioequivalent to Biktarvy Tablets, 50 mg/200 mg/25 mg of Gilead Sciences, Inc., and indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg, it added. Citing IQVIA MAT July 2025 data, Lupin said the Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets (Biktarvy) had

Indian drugmakers gear up for ₹600-800 cr insulin pen market post-Novo exit

Novo Nordisk to phase out insulin pens and cartridges in India; Eris, Wockhardt and Lupin prepare to capture Rs 600-800 crore market opportunity from FY26 onwards

7 out of 10 digital projects in India's pharma sector fail: Vector study

Vector Consulting Group study finds pharma firms spend up to ₹75 cr annually on IT systems, but 70% of digital projects fail due to adoption gaps and poor execution